Miami, FL – January 18, 2019 ( NewsWire) —, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Exactus, Inc. (OTCQB: EXDI).

Exactus, Inc., a life science company, focuses on developing and commercializing point-of-care diagnostics for measuring proteolytic enzymes in the blood. The company is developing FibriLyzer device to address the shortcomings of the viscoelastometric devices and clinical tests, such as D-dimer, as well as euglobulin lysis test; and MatriLyzer, a diagnostic device to detect the recurrence of cancer. 

Average daily volume for EXDI is 213 thousand shares. Shares have traded 55% higher with 179 thousand shares traded in the morning hours of trading.

Exactus, Inc.Press Release:

Enters into Supply and Development Agreement with Ceed2Med, LLC

GLEN ALLEN, VA / ACCESSWIRE / January 17, 2019 / Exactus Inc. (EXDI) is pleased to announce its entrance into the CBD market in conjunction with Ceed2Med, LLC’s (“C2M”) acquisition of a controlling ownership interest in Exactus, Inc. and a Master Product Development and Supply Agreement with Ceed2Med, LLC for hemp-based Cannabidiol (“CBD”) products with full genetic traceability. C2M operates and manufactures at cGMP facilities and processes raw material through a number of facilities in order to produce phyto-cannabinoid rich ingredients, including isolates, distillates, water soluble, and proprietary formulations. Exactus has a number of hemp-based CBD products in the pipeline and expects to offer tinctures, edibles, capsules, topical solutions and animal health products manufactured by C2M commencing the first quarter of 2019. C2M has committed 2,500 kilograms annually to Exactus. The founders of C2M established their first CBD business in 2014 and are leaders in CBD innovation.

In December 2018, President Trump signed the $867 billion Farm Bill which recharacterized hemp to the lowest-level listed drug (schedule 5). This clarified that mass hemp production in the United States is federally lawful, as is its transportation across state lines. Hemp is defined in the United States as cannabis with less than 0.3% Tetrahydrocannabinol (“THC”). CBD, a non-psychoactive cannabinoid found in cannabis, has had a surge in popularity over the past several years based on a wide range of potential health benefits and uses.

Philip Young, CEO of Exactus said, “We are thrilled to have such a highly respected partner as we create a new business model in the hemp marketplace. By applying the highest standards, from the initial seed selection all the way through the production and distribution of the commercial product, we plan to be a leader in quality, innovation and commercialization.” Young further commented, “This quality will be evident and part of every product line we produce, whether it is for our proprietary product line or for other commercial partners who want to access our product development pathway.”

Emiliano Ailo, Co-Founder of Ceed2Med added, “Partnering with Exactus is an exciting opportunity for our company. It is an honor to work with a company that has the same commitment to quality and a desire to lead the hemp marketplace with the highest standards. We believe our scientific commitment from seed selection, through cultivation, harvesting and manufacturing, combined with our innovative seed-to-sale traceability is setting the standard in the hemp market and ensures premium pricing and higher product safety over others”

For information about our products and availability please call 804-205-5036 or email,

About Exactus:

Exactus, Inc. is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, THC free CBD and point of care diagnostics.

Forward Looking Statements:

This press release includes forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to, the impact of competitive firms, the ability to meet regulatory requirements, the ability to manage growth, the ability to acquire and retain clientele, acquisitions of technology, equipment, or human resources, the ability to access new capital, the effect of economic business conditions, and the ability to attract and retain skilled personnel. We are not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

For more information:

Company Contacts:

Corporate Communications Contact:
Tim Ryan, EVP, Director

Philip J. Young, Chairman and CEO

SOURCE: Exactus Inc.

About is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies.  Through its evolution, found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization.  We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth.  Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community.  Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks., or its associates may have a position either long or short in any company mentioned herein. Please read our full disclosure, which can be found here, Please consult an investment professional before investing in anything viewed within this article or any other portion of In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the website.

Add a Comment to this Post